5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Pipeline Review, H1 2018

  • ID: 4531938
  • Drug Pipelines
  • 66 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Adamed Sp z oo
  • Astellas Pharma Inc
  • H. Lundbeck AS
  • Johnson & Johnson
  • Sumitomo Chemical Co Ltd
  • MORE
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Pipeline Review, H1 2018

Summary:

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report 5-Hydroxytryptamine Receptor 7 - Pipeline Review, H1 2018, outlays comprehensive information on the 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - 5-HT7 receptor is a member of the GPCR superfamily and it is activated by the serotonin (5-HT). The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It plays an important role in autistic disorder and other neuropsychiatric disorders. The molecules developed by companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 2 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Genetic Disorders and Respiratory which include indications Autism, Bipolar Disorder (Manic Depression), Psychiatric Disorders, Major Depressive Disorder, Schizophrenia, Anxiety Disorders, Attention Deficit Hyperactivity Disorder (ADHD), Cognitive Disorders, Fragile X Syndrome, Idiopathic Pulmonary Fibrosis, Inflammatory Pain, Migraine, Neuropathic Pain, Psychosis, Pulmonary Arterial Hypertension, Schizoaffective Disorder and Social Anxiety Disorders (SAD).

Furthermore, this report also reviews key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)
  • The report reviews 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics and enlists all their major and minor projects
  • The report assesses 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Adamed Sp z oo
  • Astellas Pharma Inc
  • H. Lundbeck AS
  • Johnson & Johnson
  • Sumitomo Chemical Co Ltd
  • MORE
Introduction

Report Coverage

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Overview

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Companies Involved in Therapeutics Development

Adamed Sp z oo

Astellas Pharma Inc

H. Lundbeck AS

Johnson & Johnson

Reviva Pharmaceuticals Inc

Sumitomo Chemical Co Ltd

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Drug Profiles

ADN-1184 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADN-3662 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DDD-028 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-18038683 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lurasidone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-5063 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SERx-519 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Alpha 2 Adrenergic Receptor and Antagonize 5-HT7 and 5-HT5A Receptors for Psychiatric Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for Migraine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vortioxetine hydrobromide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Dormant Products

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Discontinued Products

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Product Development Milestones

Featured News & Press Releases

Apr 20, 2018: Sunovion Announces Health Canada Approval of Latuda (lurasidone HCl) to Treat Adolescents (13 to 17 years of age) with Bipolar Depression

Apr 18, 2018: Sumitomo Dainippon Pharma Announces U.S. Appellate Court Decision on Substance Patent Infringement Lawsuit Regarding LATUDA

Apr 10, 2018: Reviva Pharmaceuticals Receives FDA Orphan Designation for RP5063 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Mar 06, 2018: Sunovion Receives FDA Approval of Supplemental New Drug Application (sNDA) for Use of Latuda (lurasidone HCl) in the Treatment of Bipolar Depression in Pediatric Patients (10 to 17 Years of Age)

Feb 23, 2018: Sumitomo Dainippon Pharma Filed Patent Infringement Lawsuits Regarding LATUDA in US

Feb 14, 2018: Sumitomo Dainippon Pharma Filed Patent Infringement Lawsuits Regarding LATUDA in the United States

Dec 04, 2017: Lundbeck’s Brintellix approved in China

Oct 27, 2017: Sunovion Presents Data from Phase 3 Studies of Latuda (lurasidone HCl) in Children and Adolescents with Bipolar Depression

Oct 17, 2017: Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting With FDA on RP5063 for the Treatment of Pulmonary Arterial Hypertension

Sep 14, 2017: Sunovion to Present Data on LATUDA at the 2017 Psych Congress

Jul 21, 2017: Sunovion’s Latuda (lurasidone HCI) Receives Health Canada Approval to Treat Adolescents with Schizophrenia

Jun 30, 2017: Sunovion Announces FDA Acceptance for Review of Supplemental New Drug Application for Latuda for the Treatment of Bipolar Depression in Children and Adolescents

Jun 23, 2017: Lundbeck and Takeda receive Complete Response Letter from the FDA for Trintellix (vortioxetine) sNDA

Jun 23, 2017: Lundbeck and Takeda receive Complete Response Letter from the FDA for Trintellix sNDA

Jun 09, 2017: Sumitomo Dainippon Pharma Announces Topline Results from a Phase 3 Study of Lurasidone, an Atypical Antipsychotic Agent, in the Treatment of Patients with Bipolar l Depression

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Adamed Sp z oo, H1 2018

Pipeline by Astellas Pharma Inc, H1 2018

Pipeline by H. Lundbeck AS, H1 2018

Pipeline by Johnson & Johnson, H1 2018

Pipeline by Reviva Pharmaceuticals Inc, H1 2018

Pipeline by Sumitomo Chemical Co Ltd, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Adamed Sp z oo
  • Astellas Pharma Inc
  • H. Lundbeck AS
  • Johnson & Johnson
  • Reviva Pharmaceuticals Inc
  • Sumitomo Chemical Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll